• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

March 24, 2020

View Archived Issues
Handshake_global2.png

Cytomx Probody language charms Astellas; tie-up potential $1.6B-plus

Cytomx Therapeutics Inc. CEO Sean McCarthy told BioWorld that the longish hiatus between deals broken by the tie-up with Astellas Pharma Inc. was “very deliberate. Over that period of time, we were generating our first clinical data to get experience with how the technology works in cancer patients with our first two lead programs,” both of which have reached the phase II stage. Read More
Money-financing

Iaso closes $60M series B to advance anti-BCMA CAR T therapy

BEIJING – Cell therapies specialist Nanjing Iaso Biotherapeutics Co. Ltd. pocketed $60 million in a series funding B round to advance its CT-103A, an anti-BCMA CAR T therapy candidate for multiple myeloma, among other plans. Read More

Junshi pushes COVID-19 neutralizing antibodies to clinic; IPO on STAR next

BEIJING – Shanghai Junshi Biosciences Ltd. is developing neutralizing antibodies as a potential treatment for COVID-19, and the program will move on to clinical trials soon. Meanwhile, the biotech is set to launch a pre-revenue IPO on Shanghai’s STAR market. Read More
australia-coronavirus-covid-19.png

As Australia shuts its borders, the country looks within to manage COVID-19 pandemic

PERTH, Australia – As Australia closes its borders to all non-citizens and non-residents, it looks within the country for solutions to manage the worsening COVID-19 pandemic. Read More
Coronavirus punch

Moving in record time, industry, government, investors focus on one mission: Beat COVID-19

Business as usual only three months ago has transformed into health care industry overdrive as biopharma and med-tech companies scramble to test and scale-up treatments, vaccines and diagnostics to address COVID-19. Read More
IPO-coins.png

Innocare launches $288M IPO on HKEX, aims to advance BTK inhibitor

BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, made a strong debut to raise $288 million on the Hong Kong Stock Exchange (HKEX) on March 23, marking the second biggest IPO in the city since the beginning of this year. Read More
Antibody pic

Celltrion reaches milestone on COVID-19 super antibody

HONG KONG – Korean biopharma Celltrion Inc. said it’s halfway through the process of creating a super antibody to reign in the COVID-19 novel coronavirus that has claimed almost 13,000 lives globally. Read More

Policy advocates propose measures for clinical disruptions in China

BEIJING – China was the first country to face serious disruptions in clinical trials caused by COVID-19, and policy advocates in the country moved quickly to identify lessons for future outbreaks. Read More
Coronavirus-paper-dolls

Despite disruptions, COVID-19 could have silver linings for biotech industry

BEIJING – The COVID-19 pandemic has temporarily impacted partnerships and investment opportunities, but it has also prompted other forms of collaboration within the biotech community. Read More

Targeting glycosylated PD-1 induces potent antitumor immunity

Targeting glycosylated PD-1 immune checkpoint may be a promising new cancer immunotherapeutic strategy, according to a collaborative study led by Taiwanese researchers, which was reported online in Cancer Research. Read More

First repurposing trial for COVID-19 falls flat

The first attempt at using existing drugs to treat patients infected with SARS-CoV-2 has yielded disappointing results. Read More
RoActemra

Genentech moves Actemra into phase III COVID-19 trial

DUBLIN – The Genentech arm of Roche Holding AG plans to move its interleukin-6 inhibitor, Actemra, into a global phase III trial in patients with severe pneumonia associated with COVID-19 infection. Read More

Other news to note for March 24, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Acadia, Adaptive, Allovir, Amneal, Aqualung, Arrowhead, Biontech, Cannabics, Cellenkos, Celltex, Cel-Sci, Codexis, Cytocom, Eli Lilly, Entos, E-therapeutics, Fujifilm, Fujitsu, Generex, Geovax Labs, Ibio, Immix, Immune, Junshi, Mannkind, Moleculin, Montreal Heart Institute, Nascent, Neoimmunetech, Neuren, Novan, Olix, Pfizer, Pharnext, Pluristem, Polarisqb, Regeneron, Resverlogix, Revive, Ribomic, Roche, Roivant, Signpath, Smartpharm, Soligenix, Sorrento, Sosei, Stabilitech, Takeda, Tarveda, Ubix, Vaxart, Vaxxas, WPD, Ziphius. Read More

Financings for March 24, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: IMV, Lattice Biologics, Tiziana Life Sciences. Read More

Appointments and advancements for March 24, 2020

New hires and promotions in the biopharma industry in Asia-Pacific, including: Epimab Biotherapeutics, I-Mab Biopharma, Sumitomo Dainippon Pharma. Read More
Courts2.png

Regulatory front for March 24, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: 340B Health, Department of Health and Human Services, FDA, Health Resources and Services Administration, Institute for Clinical and Economic Review, Medicines and Healthcare products Regulatory Agency. Read More

Clinical data for March 17-23, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Cytodyn, Genentech, Humanigen, Immutep, Inxmed (Shanghai) Co., Recce. Read More

Regulatory actions for March 17-23, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Anheart, Applied DNA Sciences, Astrazeneca, Bellerophon, Can-Fite, Cansino Biologics, Cytodyn, Genentech, Hansoh, Merck, Novartis, Synairgen, Takis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe